Status:
COMPLETED
Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure
Lead Sponsor:
University Hospital, Essen
Conditions:
Heart Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Evaluating the additional value of Macrophage Migration Inhibitory factor (MIF) in cardiovascular diseases when assessed in clinical routine.
Eligibility Criteria
Inclusion
- All patients presenting with symptoms of heart failure to the West-German Heart and Vascular Center according to the definition of the ESC 2016.
- Patients fulfilling criteria for the diagnosis of HFrEF
- Patients fulfilling criteria for the diagnosis of HFpEF
- Patients fulfilling criteria for the diagnosis of HFmrEF
- Patients presenting with dyspnea according to the NYHA classification I-IV, elevated BNP/NT-proBNP levels and echocardiographic findings of heart failure.
Exclusion
- Age \< 18 years
- Patients with symptoms of heart failure without fulfilling the criteria of the ESC guidelines 2016
- Denial to participate
Key Trial Info
Start Date :
March 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03232671
Start Date
March 1 2016
End Date
September 1 2020
Last Update
November 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Essen
Essen, North Rhine-Westphalia, Germany, 45147